Home > Riviste > Italian Journal of Dermatology and Venereology > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3) > Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3):333-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3):333-7

DOI: 10.23736/S0392-0488.17.05043-X

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series

Sara TAMBONE 1, Maria C. FARGNOLI 1, Rodolfo CAPIZZI 2, Ketty PERIS 2

1 Department of Dermatology, University of L’Aquila, L’Aquila, Italy; 2 Institute of Dermatology, Catholic University of Rome, Rome, Italy


PDF


BACKGROUND: In clinical studies, imiquimod 3.75% was shown to detect and treat actinic keratosis (AK) lesions across an entire sun-exposed field such as the full face or balding scalp. The aim of this study was to evaluate imiquimod 3.75% in a real-life clinical setting.
METHODS: Ten AK patients applied imiquimod 3.75% to the full face or scalp once-daily in two 2-week treatment cycles separated by a two-week treatment-free interval and were followed-up eight weeks later. Seven patients rated imiquimod 3.75% versus prior treatments (cryotherapy, photodynamic therapy, diclofenac sodium 3%, imiquimod 5%, ingenol mebutate).
RESULTS: The median clinical lesion count at baseline was 12.5. This increased to a median Lmax (maximum lesion count during treatment) of 22.5 as imiquimod 3.75% unmasked previously invisible subclinical lesions. At final follow-up, the median lesion count was 0. Local skin reactions such as erythema, scabbing and erosion occurred during each treatment cycle and were easy to manage. All patients considered imiquimod 3.75% easier to apply than prior treatments and 5 reported fewer or similar side effects.
CONCLUSIONS: In this cohort, imiquimod 3.75% effectively cleared clinical and subclinical lesions across the entire affected field and was well tolerated.


KEY WORDS: Keratosis, actinic - Therapeutics - Imiquimod

inizio pagina